NASDAQ:CELG - Celgene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$85.10 -0.24 (-0.28 %)
(As of 07/23/2018 07:41 AM ET)
Previous Close$85.34
Today's Range$84.53 - $85.75
52-Week Range$74.13 - $147.17
Volume4.82 million shs
Average Volume5.55 million shs
Market Capitalization$61.68 billion
P/E Ratio12.44
Dividend YieldN/A
Beta1.43
Celgene logoCelgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Debt-to-Equity Ratio3.92
Current Ratio2.53
Quick Ratio2.36

Price-To-Earnings

Trailing P/E Ratio12.44
Forward P/E Ratio11.21
P/E Growth0.54

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales4.74
Cash Flow$7.6186 per share
Price / Cash11.17
Book Value$8.79 per share
Price / Book9.68

Profitability

EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins20.73%
Return on Equity72.92%
Return on Assets17.48%

Miscellaneous

Employees7,467
Outstanding Shares724,830,000
Market Cap$61,682.79

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene declared that its Board of Directors has authorized a stock buyback program on Thursday, May 24th 2018, which permits the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 5.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) issued its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.96 by $0.09. The biopharmaceutical company had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.47 billion. Celgene had a net margin of 20.73% and a return on equity of 72.92%. The business's revenue was up 19.4% on a year-over-year basis. During the same quarter last year, the business posted $1.68 earnings per share. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share guidance of $8.45 for the period, compared to the Thomson Reuters consensus estimate of $8.45. The company issued revenue guidance of $14.8 billion, compared to the consensus revenue estimate of $14.81 billion.

What price target have analysts set for CELG?

33 brokerages have issued 1 year price targets for Celgene's stock. Their forecasts range from $85.00 to $166.00. On average, they expect Celgene's share price to reach $123.5185 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price. View Analyst Ratings for Celgene.

What is the consensus analysts' recommendation for Celgene?

33 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 1 sell rating, 12 hold ratings and 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene has been sailing in troubled waters since last October, after the company announced the failure of a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn’s disease, and the discontinuation of the extension trial, SUSTAIN (CD-004), following a recommendation from the Data Monitoring Committee, which assessed overall benefit/risk during a recent interim futility analysis. In December 2017, a late-stage study on its lead cancer drug Revlimid in combination with Roche Holdings’ (RHHBY) Rituxan failed. Moreover, Celgene received Refusal to File letter earlier in 2018 from the FDA regarding its New Drug Application for multiple sclerosis candidate, ozanimod. Shares have underperformed the industry in the last six months. In a bid to revive its pipeline, Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline. Luspatercept looks promising as well. Estimates are static ahead of Q2 results." (7/18/2018)
  • 2. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)
  • 3. Mizuho analysts commented, "We note that the language of highly statistically significant" results for the primary endpoint was used again. BOTTOM LINE: This trial was largely expected to work (Ph 2 data was encouraging, and MEDALIST worked) … probably ~$1 of additional DCF value creation… relatively small indication. Good incremental win for CELG." (7/10/2018)
  • 4. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)
  • 5. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)

Are investors shorting Celgene?

Celgene saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 15,381,014 shares, a drop of 35.8% from the June 15th total of 23,941,180 shares. Based on an average daily volume of 6,524,272 shares, the days-to-cover ratio is presently 2.4 days. Approximately 2.1% of the company's shares are sold short. View Celgene's Current Options Chain.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg, Exec. VP, CFO & Chief Accounting Officer (Age 62)
  • Dr. S. J. Rupert Vessey, EVP, Pres of Research & Early Devel. (Age 53)
  • Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
  • Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

News stories about CELG stock have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene earned a media sentiment score of 0.15 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Celgene's major shareholders?

Celgene's stock is owned by many different of institutional and retail investors. Top institutional investors include Swedbank (0.54%), Oaktop Capital Management II L.P. (0.28%), NN Investment Partners Holdings N.V. (0.25%), Baillie Gifford & Co. (0.12%), Retirement Systems of Alabama (0.08%) and Factory Mutual Insurance Co. (0.08%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Mark J Alles, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Pendal Group Ltd, FCG Advisors LLC, Assenagon Asset Management S.A., Oaktop Capital Management II L.P., TIAA FSB, Atwood & Palmer Inc. and Hartford Investment Management Co.. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael D Casey and Terrie Curran. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was bought by a variety of institutional investors in the last quarter, including Swedbank, LGT Capital Partners LTD., Gateway Investment Advisers LLC, ADAMCAPITAL Gestao de Recursos Ltda., Gofen & Glossberg LLC IL, Calamos Advisors LLC, Nisa Investment Advisors LLC and Rhenman & Partners Asset Management AB. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $85.10.

How big of a company is Celgene?

Celgene has a market capitalization of $61.68 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  1,800 (Vote Outperform)
Underperform Votes:  598 (Vote Underperform)
Total Votes:  2,398
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.